Founder, Chairman & CEO
Dr. Jaikaria is trained as a medical scientist and brings over twenty years of Financial Markets, business leadership & deep scientific experience to SGN Nanopharma. Dr. Navdeep Jaikaria founded SGN and its Indian subsidiary, New India Biopharma Pvt. Ltd., in 2010 and has successfully guided SGN into a cutting edge, commercial stage, nanotherapeutics company. Before founding SGN, Dr. Jaikaria was a consistently top ranked Biotechnology Equity Research Analyst on Wall Street and won several distinctions including one of the five best stock-pickers in Biotechnology in the Wall Street Journal’s annual “Best on the Street” Analysts survey in 2007. During his tenure on Wall Street, he held several positions. He was a Principal and served as a Managing Director & Head of Equity Research for Rodman and Renshaw, New York; Senior Vice President & Senior Biotechnology Equity Research Analyst at Leerink Swann & Co.; Senior Equity Research Analyst covering large and mid-cap biotechnology companies at Mehta Partners – a global health care hedge fund with over $100MM under management. He covered over 50 Biotechnology and Biopharmaceutical companies and his coverage universe spanned several therapeutic class areas. Dr. Jaikaria served on several industry-focused and investor panels and provided input to the United States Senate Health Committee on Bio-defense issues. His opinions were widely cited in print and broadcast media including The Wall Street Journal, Financial times, Businessweek, Forbes, CNNfn, CNBC and CNN. Dr. Jaikaria obtained his B.Sc. from All India Institute for Medical Sciences, New Delhi in Human Biology (Rank II), Ph.D. at the New York Medical College in Cell Biology & Anatomy and post-doctoral fellowship at The Rockefeller University, New York.
Vice President, R&D and Regulatory Affairs
Dr. Pranav Patel is Vice President, R&D at SGN Nanopharma. He has over 23 years of pharmaceutical nous and generic drug research and development experience in the US and India and has more than 22 peer-reviewed publications and patents. Additionally, he has extensive experience developing “controlled drugs” under DEA approvals and as a DEA liaison. At SGN, he has been instrumental in creating the robust MNP Platform-based pipeline and developing many Cannabinoid based products to treat numerous conditions. Before SGN, Dr. Patel was previously Chief Scientific Officer at Aurex Laboratories, where he helped develop the generic versions of many soft gelatin capsules. Before that, he was the Director of R&D At Navinta LLC, where he helped develop and commercialize many generic drugs for US FDA approval and ANDA/DMF filings.
Dr. Patel obtained his Ph.D. in Medicinal Chemistry from the Florida Institute of Technology. During his doctoral and post-doc research under Dr. Joshua Rokach (world-renowned for pioneering the synthesis of several inflammatory mediators and drugs, including the blockbuster asthma drug Singulair), Dr. Patel was extensively involved in prostaglandin and isoprostane research geared towards new drug development for the treatment of many chronic diseases like Asthma, Alzheimer’s, atherosclerosis and cancer. He is currently working on a nose-to-brain drug delivery system with Dr. Sanchez-Ramos (Neurology, USF). Additionally, he is developing treatments for traumatic brain injury in collaboration with Dr. Shyam Mohapatra (Pharmacy, USF).
Chief Operating Officer
Accomplished business leader with over 20 years of experience in Specialty Pharmaceuticals and Consumer Healthcare. He was formerly Country Head of Shire/Baxalta/Takeda in India and Novartis Consumer Health in South East Asia. He delivered strong and sustainable growth in businesses through organic levers like new product launches and deeper market access and inorganic levers such as M&A and Licensing-in opportunities. He develops an aspirational and shared plan with a strong leadership team, making bold choices, pre-empting risks, and follows through with a focus on execution. He has proven experience in operationalizing robust governance processes needed to execute growth opportunities, manage transitions and address risks & challenges. He is known to build a culture of resilience through positive leadership, generative conversations, and a habit of cross-functional collaboration. He brings a unique mix of global roles such as Strategic Planning & Business Development, and Country Leadership across the USA, Europe, South East Asia, and India. He has a Bachelor in Mechanical Engineering from Delhi University and an MBA from Cranfield School of Management in the UK.
As the Chief Operating Officer at SGN, he is part of the leadership team transforming the company to deliver on an explosive growth agenda. Vineet has implemented processes and operating systems that bring the Leadership Team together on a common platform with clear roles and accountabilities while building a strong operating rhythm to monitor day-to-day execution. He has been instrumental in creating an aggressive business development pipeline with deal closures and helped initiate various Clinical trials and build out a robust regulatory & supply chain backbone for the company.
Chief Business Officer
Mr. Sanjiv Kapur is a successful entrepreneur with over 25 years of production, marketing and business development experience. He has a BE in Mechanical Engineering and a Masters in Environmental Engineering from University of Southern California.
Chief Financial Officer
Mr. Srivastava brings over 15+ years of cross-border experience in corporate finance and executive leadership; 9+ years of working at JP Morgan investment bank and 7+ years of working as the CFO for several small to mid-size companies from healthcare, technology to retail. He also served as the CFO for a global not-for-profit in the US and India that ran a healthcare NGO in India. Academic background includes a BS in Chemical Engineering from the University of Rochester and an MBA in Finance & Marketing from New York University – Stern School of Business.
Dr. Rahul Singhvi is a global leader in the Life Sciences industry and serves as the Chief Executive Officer of National Resilience, Inc. Most recently, Rahul was an Operating Partner at Flagship Pioneering, a Boston-based life sciences innovation firm where he was responsible for founding and operating companies launched from Flagship’s innovation foundry, Flagship labs. Before joining Flagship, Rahul was the Chief Operating Officer of Takeda’s Vaccine Business Unit where he was responsible for worldwide vaccine CMC and manufacturing operations. During his six-year tenure at Takeda, the vaccine business grew to over 500 employees and created an industry-leading late-stage pipeline of vaccine candidates against dengue, norovirus, and zika. Before Takeda, Rahul was President and CEO of Novavax, Inc. (Nasdaq: NVAX). Rahul’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing. Dr. Singhvi graduated as the top-ranked chemical engineer from the Indian Institute of Technology, Kanpur, India and obtained both his M.S. and Sc.D. chemical engineering degrees from MIT. He received an MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.
Dr. Sunil Gupta, is a leading, nationally recognized retinal surgeon in the US, a successful entrepreneur, and a health care pioneer. He founded the Retina Specialty Institute, and is the co-founder and chief medical officer of USRetina—one of the largest associations of retina physicians in the United States—as well as the founder, chairman and chief medical officer of IRIS: Intelligent Retinal Imaging Systems, an FDA-cleared, cloud based, telemedicine tool for assessment of retinal eye disease in the primary care setting. The award-winning IRIS team is on a mission to end preventable blindness due to Diabetic Retinopathy and other conditions. Dr. Gupta was the past chairman of the Andrews Institute Ambulatory Surgery Center and serves on the board of the Andrews Research & Education Institute. Dr. Gupta has participated in over 30 clinical studies.
Dr. Gupta presently serves on the Advisory Boards of several leading Multinational Pharmaceutical companies including Novartis, Allergan and Genentech. He obtained his B.Sc. in Chemical Engineering from the University of Washington, Seattle and his MD from University of Cincinnati College of Medicine.
Mr. Sampaio was most recently President, Latin America, Pfizer Consumer Healthcare Division (2012-2019) and before that served as General Manager, Brazil, for Wyeth Consumer Healthcare Division. He brings his extensive global experience in general management, marketing and sales excellence, business development and change management, supporting Fast-Moving Consumer Goods (FMCG) across Food, Personal Care as well as Over the Counter (OTC) Healthcare business sectors to SGN Nanopharma and its OTC subsidiary, “c’bella naturals.” He is actively leading our business development efforts in South America.
Dr. Sanchez-Ramos is a Professor of Neurology at the University of South Florida in Tampa where he holds the Helen Ellis Endowed Chair for Parkinson’s Disease Research and is Director of the HDSA Center of Excellence for Huntington’s Disease. He is also Medical Director of the non-profit Parkinson Research Foundation based in Sarasota FL. In addition to teaching and attending to patients with Movement Disorders, he has directed basic research projects in neurodegeneration, neurotoxicology, and adult stem cell biology. Dr. Sanchez-Ramos is actively engaged in studying the role of the endocannabinoid system in brain repair following traumatic brain injury. Dr. Sanchez-Ramos, in collaboration with SGN Nanopharma, has an actively funded research program from the State of Florida (Florida I4 HiTech Grant) entitled “Nanoformulations of Cannabinoids for Nose to Brain Delivery.” He has over 200 publications in peer-reviewed journals.
Dr. Sanchez-Ramos received a Ph.D. in Pharmacology and Physiology from the University of Chicago and a medical degree (M.D.) from the University of Illinois. He trained in Neurology at the University of Chicago and as a Fellow in Movement Disorders at the University of Miami.
Dr. Todd Margolis is a Key Opinion Leader in Ophthalmology and since 2014 serves as the Alan and Edith Wolff Distinguished Professor and Chairman of the Department of Ophthalmology and Visual Sciences at Washington University, St Louis. Prior to that, Dr. Margolis served for 14 years as Director of the F.I. Proctor Foundation. His main research focus is on infectious and inflammatory ocular disease with a particular interest in herpesvirus infections of the eye. He has over 200 peer-reviewed publications and has trained 18 postdoctoral fellows and over 100 clinical fellows. He has received a number of awards including the Jules Stein Vision Research Award, RPB Career development Award, RPB Lew Wasserman Merit Award, RPB Senior Scientific Investigator Award, faculty AOA award, and 2012 Heed Award. He has served on a number of NIH study sections, on the NEI council, as executive editor of the American Journal of Ophthalmology, and as president of ARVO, the largest society for vision research. Dr. Margolis graduated with Honors and Distinction in Biology from Stanford University, followed by both an MD and Ph.D. (in Neuroscience) from UCSF. After completing his Ophthalmology residency at UCSF he completed a Heed Fellowship in Cornea, External Diseases and Uveitis at the F.I. Proctor Foundation followed by postdoctoral training in viral pathogenesis at UCLA. He joined the UCSF faculty in 1991 and by 1999 was promoted to full professor, and Director of the F.I. Proctor Foundation, an organized research unit of the University of California.
Dr. Miller is a leading plastic surgeon in Boston who serves on the faculty staff of the Harvard Medical School with full operating privileges at Beth Israel Deaconess Hospital, New England Baptist Hospital (Chief of Plastic Surgery), and the Massachusetts Eye and Ear Infirmary. He is actively involved in the development of new skincare technologies and cosmetic products. Dr. Miller is an investor in SGN and is helping to develop the anti-wrinkle & Alopecia franchises.
Dr. Warren is a well-known plastic and Craniofacial surgeon and the Vice-Chairman of Plastic Surgery, New York University Medical Center. Dr. Warren is on the editorial board of several International Medical Journals and has over 200 publications. Dr. Warren has diverse interests including tissue engineering, outcomes research, and regenerative medicine. Dr. Warren is an investor in SGN and is helping us develop the anti-wrinkle & Alopecia franchises.
A leading ophthalmologist in India Dr. Reddy is the Founder and Co-Chairman of a super specialty eye care hospital in Hyderabad which is India’s first Lasik Centre. He is a member of the Advisory Board of Bausch & Lomb and an investor in SGN.
Internationally known ophthalmologist and corneal and refractive surgery specialist. He is currently an Associate Professor of ophthalmology at Rush University Medical Center in Chicago, IL. In addition to a busy clinical and surgical practice, Dr. Majmudar is an active participant in clinical research and is an active member of the American Society of Cataract and Refractive Surgery as well as the American Academy of Ophthalmology. He recently received the Academy’s Senior Achievement Award. He is an International Council Representative from the United States for the International Society of Refractive Surgery. Dr. Majmudar also serves on the medical advisory board for several commercial entities. R. Majumdar is an investor in SGN.
Over 25 years of experience in federal government contracting and commercial sales in business development, capture management, proposal development and management, technical solution development, and program implementation and management. Mr. Adivi brings a unique combination of technical talent, with his strong engineering background, and years of business experience to successfully capture technology business, as evidenced by the hundreds of millions of dollars of business he has won for his companies over his career. He has successfully served in key technology management roles at Canonical, URS, NCI, Intelect, Southwestern Bell Technology Resource Inc., Texas Instruments, and Lockheed Missiles and Space Company. Mr. Adivi was co-founder of Vesta Broadband Services, a startup that specialized in developing and licensing video-delivery infrastructure software. He received a Bachelor of Technology (Honors) Degree in Manufacturing Engineering from the Indian Institute of Technology, Kharagpur, India, and a Master of Science Degree in Mechanical Engineering from the University of Hawaii at Manoa.
Dr. Patel is an accomplished leader and a successful entrepreneur. He brings strong execution skills and over 23 years of manufacturing & international business development experience to SGN. In 1992, Dr. Patel founded National Biochemicals Corp which manufactures and supplies raw materials to the life science industry. He served as its President & CEO until Feb 2015, when he sold the company to VWR International. Dr. Patel obtained his Ph.D. in Biochemistry in 1980 from the University of Saskatchewan, Canada. He is an investor in SGN.